AstraZeneca’s Imfinzi Received the EU’s CHMP Positive opinion for the treatment of Hepatocellular Carcinoma
Shots:
- The positive opinion was adopted for the new indication of Imfinzi (durvalumab) as 1L monotx. for the treatment of advanced or unresectable hepatocellular carcinoma was based on a P-III study (HIMALAYA)
- The P-III (HIMALAYA) clinical trial evaluates the safety & efficacy of Imjudo (300mg) + Imfinzi (1500, q4w) vs sorafenib in unresectable HCC patients (n=1324) with no prior systemic therapy
- Imfinzi (durvalumab) is a human PD-L1 protein and blocks PD-1 and CD80 proteins. Imfinzi in combination with Imjudo (tremelimumab) approved in unresectable HCC in the US, EU, Japan and many other countries based on the TOPAZ-1 and HIMALAYA study
Ref: European Medicines Agency | Image: AstraZeneca
*Note: This is not an original PR, this reference is taken based on European Medicines Agency website
Related News:- AstraZeneca Received NMPA Approval for Imfinzi + CT to Treat Patients with Locally Advanced/metastatic Biliary Tract Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
